Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label alzheimers plaque. Show all posts
Showing posts with label alzheimers plaque. Show all posts

Wednesday, October 11, 2023

Mystery Behind Neuron Death in Alzheimer’s Decoded

 

Because of your extra risk of dementia from your stroke, does your hospital and doctor have enough functioning brain cells to use this to prevent brain cell death? 

Do you prefer your doctor and hospital incompetence NOT KNOWING OR NOT DOING anything on this?

Your risk of dementia, has your doctor told you of this?  Your doctor is responsible for preventing this!

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

The latest here:

Mystery Behind Neuron Death in Alzheimer’s Decoded

Summary: Researchers have unveiled the mystery behind neuron death in Alzheimer’s disease. A groundbreaking study reveals that neurons undergo a programmed cell death, necroptosis, when exposed to amyloid plaques and tau tangles, hallmark proteins linked to Alzheimer’s. The study pinpoints an RNA gene called MEG3 as a potential key player in this process. This pivotal discovery provides promising pathways for future treatments.

Key Facts:

  1. Neurons exposed to amyloid plaques and tau tangles initiate a cell death process called necroptosis.
  2. An RNA gene, MEG3, has been identified as a critical component in this neuron death mechanism, as seen in Alzheimer’s patients.
  3. Utilizing a new model, researchers observed that only human neurons showed Alzheimer’s characteristics, suggesting human-specific factors in the disease.

Source: Medical Research Council

A research team has finally discovered how neurons die in Alzheimer’s disease (AD). The team is led by Professor Bart De Strooper at VIB-KU Leuven and the UK Dementia Research Institute (UK DRI) at UCL and Dr. Sriram Balusu at VIB-KU Leuven.

A subject of scientific discussion in recent decades, a breakthrough research paper illustrates how neurons initiate a programmed form of cell death, known as necroptosis, when they are exposed to amyloid plaques and tau tangles. This is a hallmark misfolded proteins implicated in Alzheimer’s.

This shows neurons.
The researchers saw that levels of a molecule known as MEG3 were strongly increased in human neurons, as seen in Alzheimer’s patients. Credit: Neuroscience News

More importantly, the research team was able to prevent the death of neurons, rescuing them in the process. The discovery opens new pathways for potential future treatments.

The study sheds light on the previously murky waters of AD, revealing a potential key player in neuronal loss, an RNA gene called MEG3, and the process of necroptosis. These findings are an important step forward in furthering our understanding of the basic mechanisms underlying this complex and often misunderstood disease.

The paper, titled “MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer’s disease,” is published in Science.

Professor Bart De Strooper, group leader at UK DRI at UCL and VIB-KU Leuven Center for Brain and Disease Research, said, “Our study sheds light on the previously murky waters of Alzheimer’s disease, revealing a potential key player in neuronal loss—an RNA gene called MEG3, and the process of necroptosis. These findings are an important step forward in furthering our understanding of the basic mechanisms underlying this complex and often misunderstood disease.”

A new model to crack the Alzheimer’s enigma

One of the key challenges in understanding AD has been connecting its defining hallmarks, amyloid plaques, tau tangles, and death of neurons, to each other.

Most mouse models used in research couldn’t naturally replicate these features, leaving scientists with unanswered questions about how they relate to disease progression.

Sriram Balusu, postdoctoral researcher in the De Strooper lab and first author of the paper, said, “To bridge this gap, we created a new model, we implanted both healthy human and mouse neurons into the brains of AD mouse models. The human cells degenerated much like their counterparts in the human brain, allowing us to study them during brain aging and shine a new light on the processes underlying AD.”

Remarkably, only the human neurons, and not their rodent counterparts, displayed Alzheimer’s features seen in the brains of patients, including tau tangles, and significant neuronal cell loss.

This suggests that there may be human-specific factors at play in Alzheimer’s that standard mouse models can’t replicate.

Understanding why mouse neurons are more resilient to amyloid pathology will not only help model the disease better but might also stimulate research into pathways that protect against neurodegeneration.

The culprit behind brain cell loss

Using their new model, the team probed deeper, seeking answers on how neurons die in Alzheimer’s.

The study revealed a critical breakthrough, a pathway known as necroptosis, a form of programmed cell death, was activated in the model, leading to death of neurons.

But the discovery went even further. The researchers saw that levels of a molecule known as MEG3 were strongly increased in human neurons, as seen in Alzheimer’s patients.

Strikingly, just the presence of MEG3 alone was enough to trigger the pathway of necroptosis in human neurons in a lab setting.

The study also found that by reducing MEG3 and preventing necroptosis, researchers could in turn prevent the death of cells. More research is needed to understand how exactly MEG3 triggers necroptosis, but this discovery represents a crucial advancement in understanding how Alzheimer’s leads to the loss of neurons in the brain.

Professor De Strooper said, “Necroptosis is already an active area of drug development in cancer and ALS. While there’s much more to explore, our findings open up promising avenues for potential therapies targeting AD, alongside traditional approaches aimed at amyloid and tau.”

About this Alzheimer’s disease research news

Author: Bart De Strooper
Source: Medical Research Council
Contact: Bart De Strooper – Medical Research Council
Image: The image is credited to Neuroscience News

Original Research: Closed access.
“MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer’s disease” by Bart De Strooper et al. Science

Saturday, October 22, 2022

Treadmill Exercise Improves PINK1/Parkin-Mediated Mitophagy Activity Against Alzheimer’s Disease Pathologies by Upregulated SIRT1-FOXO1/3 Axis in APP/PS1 Mice

WHOM is going to do the human research on this? Or do we just have to guess on the time and vigorousness of this treadmill exercise and hope it works?

Treadmill Exercise Improves PINK1/Parkin-Mediated Mitophagy Activity Against Alzheimer’s Disease Pathologies by Upregulated SIRT1-FOXO1/3 Axis in APP/PS1 Mice

Abstract

Although treadmill exercise is effective against Alzheimer’s disease (AD), the molecular mechanisms underlying these effects are not fully understood. Recent literature has linked the accumulation of damaged mitochondria and defective mitophagy to AD progression. Here, we determined that abnormally activated PINK1/Parkin pathway–mediated mitophagy plays an important role in AD progression and pathogenesis in 6-month-old APP/PS1 mice. We used the lysosomal inhibitor chloroquine and demonstrated that a 12-week treadmill exercise program improved mitochondrial function, decreased accumulation of β-amyloid plaques, and ameliorated loss of learning and memory ability by enhancing PINK1/Parkin-mediated mitophagy activity in the hippocampus of APP/PS1 mice. Moreover, using the SIRT1 inhibitor EX527, we found that 12 weeks of treadmill exercise rescued PINK1/Parkin-mediated mitophagy by activating the SIRT1-FOXO1/3 axis in the hippocampus of APP/PS1 mice. These findings reveal that activating PINK1/Parkin-mediated mitophagy is a promising strategy for AD treatment, and that the SIRT1-FOXO1/3 axis is a potential candidate for the development of mitophagy enhancers.

This is a preview of subscription content, access via your institution.

Sunday, May 31, 2020

NanoDevices Trap Dangerous Alzheimer's Plaque

Which one is your doctor going to prescribe for you?(Wine? Or wait 50 years?) Does your doctor even know of your need for this?

Your chances of getting dementia.

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

5. Parkinson’s Disease May Have Link to Stroke March 2017


Wine Cleans Alzheimer's Plaque January 2020

Or this latest one only tested in mice and probably decades away from common usage? Assuming of course that your doctor and stroke hospital have enough competence/responsibility to get this research going in humans.  Can you wait that long? I'll be doing the wine thing. 

Even if this works you will then need a SPECIFIC SLEEP PROTOCOL so your glymphatic system can clear the waste from your brain while you sleep. 

NanoDevices Trap Dangerous Alzheimer's Plaque

Nanodevices are the newest weapon in medicine’s growing arsenal to fight Alzheimer’s. They capture dangerous peptides before they can assemble to form Alzheimer’s plaques in the brain. Find out how.



Alzheimer's disease is the sixth leading cause of death in the United States, affecting one in 10 people over the age of 65. Scientists are engineering nanodevices to disrupt processes in the brain that lead to the disease.

People who are affected by Alzheimer's disease have a specific type of plaque, made of self-assembled molecules called β-amyloid (Aβ) peptides, that build up in the brain over time. This buildup is thought to contribute to loss of neural connectivity and cell death. Researchers are studying ways to prevent the peptides from forming these dangerous plaques in order to halt development of Alzheimer's disease in the brain.

How it works

In a multidisciplinary study, scientists at the U.S. Department of Energy's (DOE) Argonne National Laboratory, along with collaborators from the Korean Institute of Science and Technology (KIST) and the Korea Advanced Institute of Science and Technology (KAIST), have developed an approach to prevent plaque formation by engineering a nano-sized device that captures the dangerous peptides before they can self-assemble.

The β-amyloid peptides arise from the breakdown of an amyloid precursor protein, a normal component of brain cells," said Rosemarie Wilton, a molecular biologist in Argonne's Biosciences division. "In a healthy brain, these discarded peptides are eliminated."

In brains prone to the development of Alzheimer's, however, the brain does not eliminate the peptides, leaving them to conglomerate into the destructive plaques.

"The idea is that, eventually, a slurry of our nanodevices could collect the peptides as they fall away from the cells -- before they get a chance to aggregate," added Elena Rozhkova, a scientist at Argonne's Center for Nanoscale Materials (CNM), a DOE Office of Science User Facility.

Decorating the surface

The researchers covered the surface of the new nanodevice with fragments of an antibody -- a type of protein -- that recognizes and binds to the Aβ peptides. The surface of the nanodevice is spherical and porous, and its craters maximize the available surface area for the antibodies to cover. More surface area means more capacity for capturing the sticky peptides.

To find the optimal coating, the scientists first searched previous literature to identify antibodies that have high affinity to Aβ peptides. It was important to choose an antibody that attracts the peptides but doesn't bind to other molecules in the brain. Then the team, led by Wilton, produced the antibodies in bacteria and tested their performance.

A full antibody molecule can be up to a few dozen nanometers long, which is big in the realm of nanotechnology. However, only a fraction of this antibody is involved in attracting the peptides. To maximize the effectiveness and capacity of the nanodevices, Wilton's group produced tiny fragments of the antibodies to decorate the nanodevice's surface.

Engineering and testing the nanodevice

The scientists at CNM constructed the base of the porous, spherical nanodevices out of silica, a material that has long been used in biomedical applications due to its flexibility in synthesis and its nontoxicity in the body. Coated with the antibody fragments, the nanodevices capture and trap the Aβ peptides with high selectivity and strength.

"Many attempts to prevent Alzheimer's have focused on inhibiting enzymes from cutting β-amyloid peptides off of the cell's surface," said Rozhkova, who led the project at CNM. "Our elimination approach is more direct. We've taken building blocks from nanotechnology and biology to engineer a high-capacity 'cage' that traps the peptides and clears them from the brain."

At CNM, the scientists tested the effectiveness of the devices by comparing how the peptides behaved in the absence and presence of the nanodevices. Using in vitro transmission electron microscopy (TEM), they observed a notable decline in peptide aggregation in the presence of the nanodevices. They further analyzed the interactions using confocal laser scanning microscopy and microscale thermophoresis measurement, two additional techniques for characterizing interactions at the nanoscale.

The scientists also performed small-angle X-ray scattering to study the processes that make the nanodevices porous during synthesis. The researchers performed the X-ray characterization, led by Byeongdu Lee, a group leader in Argonne's X-ray Science division, at beamline 12-ID-B of the lab's Advanced Photon Source (APS), a DOE Office of Science User Facility.

These studies supported the case that the nanodevices sequester the peptides from the pathway to aggregation by more than 90 percent compared to the control silica particles without the antibody fragments. However, the devices still needed to demonstrate their effectiveness and safety within cells and brains. Joonseok Lee -- who originally proposed this experiment at Argonne as a Director's Postdoctoral Appointee and pioneered the design for the nanodevice -- continued the study of the therapeutic potential of this device at KIST and KAIST.

"The Director's Postdoctoral Position is a rare opportunity offered at Argonne that allows for unique research projects and cross-field collaborations that might not otherwise be possible," said Rozhkova. "We have incredible minds at the lab who want to explore topics that don't fall under a predefined area of research, and this program encourages this creativity and innovation."

Models Demonstrated Safety, Efficacy

The in vivo experiments -- experiments that took place in living cells -- performed by Lee and his collaborators showed that the nanodevices are nontoxic to cells. They also tested the effectiveness of the devices in the brains of mice with Alzheimer's, demonstrating around 30 percent suppression of plaque formation in brains containing the nanodevices compared to control brains. The research on mice was conducted at KIST and KAIST in South Korea with appropriate government approvals.

This study combined the strengths of antibody engineering and nanotechnology, the power of two DOE User Facilities at Argonne and innovative collaboration resulting from the laboratory's postdoctoral program to explore a technological approach to preventing Alzheimer's.

Using a similar approach, scientists may also be able to pair the silica nanoparticles with different antibodies that target molecules related to other neurodegenerative diseases, such as Huntington's disease and Parkinson's disease, which also involve abnormal protein aggregation. The porous nanoparticles may be further upgraded for use in imaging applications including fluorescent imaging and magnetic resonance imaging.
SOURCE:
REFERENCE:
  • Huijin Jung, You Jung Chung, Rosemarie Wilton, Chang Heon Lee, Byung Il Lee, Jinyeong Lim, Hyojin Lee, Jong‐Ho Choi, Hyuno Kang, Byeongdu Lee, Elena A. Rozhkova, Chan Beum Park, Joonseok Lee. Silica Nanodepletors: Targeting and Clearing Alzheimer's β‐Amyloid Plaques. Advanced Functional Materials, 2020; 30 (15): 1910475 DOI: 10.1002/adfm.201910475

Sunday, January 12, 2020

Wine Cleans Alzheimer's Plaque

I'm sure your doctor will never prescribe this. S/he will use this instead because alcohol can never be good for you. I'd have to start drinking box wine since a bottle contains 5 glasses and I don't have a partner to drink with.

Your doctor will use this: Or just say this was in mice and not offer to get human research going.

Safest level of alcohol consumption is none, worldwide study shows

But would you prefer this result?

Wine Cleans Alzheimer's Plaque

 While a couple of glasses of wine can help clear the mind after a busy day, good research shows that it may actually help clean the mind as well. The intriguing study, which appears in the journal Scientific Reports, shows that low levels of alcohol consumption tamp down inflammation and helps the brain clear away toxins, including those associated with Alzheimer’s disease. 

“Prolonged intake of excessive amounts of ethanol is known to have adverse effects on the central nervous system,” said Maiken Nedergaard, M.D., D.M.Sc., co-director of the Center for Translational Neuromedicine at the University of Rochester Medical Center (URMC) and lead author of the study.  “However, in this study we have shown for the first time that low doses of alcohol are potentially beneficial to brain health, namely it improves the brain’s ability to remove waste.”

The finding adds to a growing body of research that point to the health benefits of low doses of alcohol. While excessive consumption of alcohol is a well-documented health hazard, many studies have linked lower levels of drinking with a reduced risk of cardiovascular diseases as well as a number of cancers. 

Wine and the Glymphatic System

Nedergaard’s research focuses on the glymphatic system, the brain’s unique cleaning process that was first described by Nedergaard and her colleagues in 2012.  They showed how cerebral spinal fluid (CSF) is pumped into brain tissue and flushes away waste, including the proteins beta amyloid and tau that are associated with Alzheimer’s disease and other forms of dementia.  Subsequent research has shown that the glymphatic system is more active while we sleep, can be damaged by stroke and trauma, and improves with exercise.

The research study, which was conducted in mice, looked at the impact of both acute and chronic alcohol exposure.  When they studied the brains of animals exposed to high levels of alcohol over a long period of time, the researchers observed high levels of a molecular marker for inflammation, particularly in cells called astrocytes which are key regulators of the glymphatic system.  They also noted impairment of the animal’s cognitive abilities and motor skills.

Animals that were exposed to low levels of alcohol consumption, analogous to approximately 2 ½ drinks per day, actually showed less inflammation in the brain and their glymphatic system was more efficient in moving CSF through the brain and removing waste, compared to control mice who were not exposed to alcohol.  The low dose animals’ performance in the cognitive and motor tests was identical to the controls.

Low Doses Beneficial, Excessive Consumption Detrimental

“The data on the effects of alcohol on the glymphatic system seemingly matches the J-shaped model relating to the dose effects of alcohol on general health and mortality, whereby low doses of alcohol are beneficial, while excessive consumption is detrimental to overall health” said Nedergaard.  “Studies have shown that low-to-moderate alcohol intake is associated with a lesser risk of dementia, while heavy drinking for many years confers an increased risk of cognitive decline.  This study may help explain why this occurs.  Specifically, low doses of alcohol appear to improve overall brain health.”


SOURCE:
AUTHORS:
  • Additional co-authors include Iben Lundgaard, Wei Wang, Allison Eberhardt, Hanna Vinitsky, Benjamin Reeves, Sisi Peng, Nanhong Lou, and Rashid Hussein with URMC. Nedergaard maintains research labs at both URMC and the University of Copenhagen in Denmark.
SUPPORT:
  • The study was funding with support from the Department of Navy’s Office of Naval Research, the National Institute of Neurological Disorders and Stroke, and the National Institute on Aging.

Sunday, June 30, 2019

MIT's Light-Therapy Decreases Alzheimer's Plaque

Does your doctor have enough gumption and brains to try this on stroke patients maybe as a preventative to your likely chance of getting dementia? Before it is totally proven out? 

I would suggest that we just hand all the problems in stroke over to MIT graduates and let them get a Nobel prize early in their career.  A competent stroke leader would look at all these incredibly smart people needing a project to graduate with and hand them all the nihilism in stroke problems. But that will never occur. We have NO STROKE LEADERSHIP, stroke is totally rudderless.

Damn it all: stroke is easy; 5 steps.
1.  Describe the problems exactly.
2.  Write thousands of RFPs to researchers/MIT grads to solve those problems.
3.  Fund them with foundation grants.
4.  Write stroke rehab protocols based on the research.
5.  Get the Nobel prize in medicine 

 

MIT's Light-Therapy Decreases Alzheimer's Plaque

VIDEO + ARTICLE:

MIT researchers substantially reduced beta-amyloid plaques in Alzheimer’s, using LED lights flickering at a specific frequency.



Helps Cells That Destroy Alzheimer's Plaque

This treatment appears to work by inducing brain waves known as gamma oscillations, which the researchers discovered help the brain suppress beta amyloid production and invigorate cells responsible for destroying the plaques.

Further research will be needed to determine if a similar approach could help Alzheimer’s patients, says Li-Huei Tsai, the Picower Professor of Neuroscience, director of MIT’s Picower Institute for Learning and Memory, and senior author of the study, which appears in the online edition of Nature.

Article continued below video...

Researchers in Li-Huei Tsai's laboratory at the Picower Institute for Learning and Memory have shown that disrupted gamma waves in the brains of mice with Alzheimer’s disease can be corrected by a unique non-invasive technique using flickering light.
Video: The Picower Institute for Learning and Memory


“It’s a big ‘if,’ because so many things have been shown to work in mice, only to fail in humans,” Tsai says. “But if humans behave similarly to mice in response to this treatment, I would say the potential is just enormous, because it’s so noninvasive, and it’s so accessible.”

Tsai and Ed Boyden, an associate professor of biological engineering and brain and cognitive sciences at the MIT Media Lab and the McGovern Institute for Brain Research, who is also an author of the Nature paper, have started a company called Cognito Therapeutics to pursue tests in humans. The paper’s lead authors are graduate student Hannah Iaccarino and Media Lab research affiliate Annabelle Singer.

“This important announcement may herald a breakthrough in the understanding and treatment of Alzheimer's disease, a terrible affliction affecting millions of people and their families around the world,” says Michael Sipser, dean of MIT’s School of Science. “Our MIT scientists have opened the door to an entirely new direction of research on this brain disorder and the mechanisms that may cause or prevent it. I find it extremely exciting.”

Brain wave stimulation

Alzheimer’s disease, which affects more than 5 million people in the United States, is characterized by beta amyloid plaques that are suspected to be harmful to brain cells and to interfere with normal brain function. Previous studies have hinted that Alzheimer’s patients also have impaired gamma oscillations. These brain waves, which range from 25 to 80 hertz (cycles per second), are believed to contribute to normal brain functions such as attention, perception, and memory.

In a study of mice that were genetically programmed to develop Alzheimer’s but did not yet show any plaque accumulation or behavioral symptoms, Tsai and her colleagues found impaired gamma oscillations during patterns of activity that are essential for learning and memory while running a maze.

Next, the researchers stimulated gamma oscillations at 40 hertz in a brain region called the hippocampus, which is critical in memory formation and retrieval. These initial studies relied on a technique known as optogenetics, co-pioneered by Boyden, which allows scientists to control the activity of genetically modified neurons by shining light on them. Using this approach, the researchers stimulated certain brain cells known as interneurons, which then synchronize the gamma activity of excitatory neurons.

40% to 50% Reduction

After an hour of stimulation at 40 hertz, the researchers found a 40 to 50 percent reduction in the levels of beta amyloid proteins in the hippocampus. Stimulation at other frequencies, ranging from 20 to 80 hertz, did not produce this decline.

Tsai and colleagues then began to wonder if less-invasive techniques might achieve the same effect. Tsai and Emery Brown, the Edward Hood Taplin Professor of Medical Engineering and Computational Neuroscience, a member of the Picower Institute, and an author of the paper, came up with the idea of using an external stimulus — in this case, light — to drive gamma oscillations in the brain. The researchers built a simple device consisting of a strip of LEDs that can be programmed to flicker at different frequencies.

Using this device, the researchers found that an hour of exposure to light flickering at 40 hertz enhanced gamma oscillations and reduced beta amyloid levels by half in the visual cortex of mice in the very early stages of Alzheimer’s. However, the proteins returned to their original levels within 24 hours.

The researchers then investigated whether a longer course of treatment could reduce amyloid plaques in mice with more advanced accumulation of amyloid plaques. After treating the mice for an hour a day for seven days, both plaques and free-floating amyloid were markedly reduced. The researchers are now trying to determine how long these effects last.

Furthermore, the researchers found that gamma rhythms also reduced another hallmark of Alzheimer’s disease: the abnormally modified Tau protein, which can form tangles in the brain.

Gamma Oscillations Clean Up

“What this study does, in a very carefully designed and well-executed way, is show that gamma oscillations, which we have known for a long time are linked to cognitive function, play a critical role in the capacity of the brain to clean up deposits,” says Alvaro Pascual-Leone, a professor of neurology at Harvard Medical School who was not involved in the research. “That’s remarkable and surprising, and it opens up the exciting prospect of possible translation to application in humans.”

Tsai’s lab is now studying whether light can drive gamma oscillations in brain regions beyond the visual cortex, and preliminary data suggest that this is possible. They are also investigating whether the reduction in amyloid plaques has any effects on the behavioral symptoms of their Alzheimer’s mouse models, and whether this technique could affect other neurological disorders that involve impaired gamma oscillations.

Two Modes of Action


The researchers also performed studies to try to figure out how gamma oscillations exert their effects. They found that after gamma stimulation, the process for beta amyloid generation is less active. Gamma oscillations also improved the brain’s ability to clear out beta amyloid proteins, which is normally the job of immune cells known as microglia.

“They take up toxic materials and cell debris, clean up the environment, and keep neurons healthy,” Tsai says.

In Alzheimer’s patients, microglia cells become very inflammatory and secrete toxic chemicals that make other brain cells more sick. However, when gamma oscillations were boosted in mice, their microglia underwent morphological changes and became more active in clearing away the beta amyloid proteins.

“The bottom line is, enhancing gamma oscillations in the brain can do at least two things to reduced amyloid load. One is to reduce beta amyloid production from neurons. And second is to enhance the clearance of amyloids by microglia,” Tsai says.

The researchers also sequenced messenger RNA from the brains of the treated mice and found that hundreds of genes were over- or underexpressed, and they are now investigating the possible impact of those variations on Alzheimer’s disease.

MORE INFORMATION:
  • The research was funded by the JPB Foundation, the Cameron Hayden Lord Foundation, a Barbara J. Weedon Fellowship, the New York Stem Cell Foundation Robertson Award, the National Institutes of Health, the Belfer Neurodegeneration Consortium, and the Halis Family Foundation.
SOURCE:

Sunday, December 16, 2018

Coffee's Phenylindanes Fight Alzheimer's Plaque

Maybe when we get some actual stroke leadership we will get what we need. A protocol of actual amounts needed each day. Precise research needed. 

We need followup and we need it NOW! Whom is going to take responsibility and get that done? 

Our fucking failures of stroke associations will DO NOTHING. Your doctor will DO NOTHING. Your stroke hospital will DO NOTHING.  You're screwed. 

And why are they doing NOTHING? Laziness? Incompetence? Or just don't care? No leadership? No strategy? Not my job?

 

Coffee's Phenylindanes Fight Alzheimer's Plaque 

VIDEO + ARTICLE:

Roasting coffee beans produces Phenylindanes. Phenylindanes uniquely prevent – or rather, inhibit – both tau and beta amyloid plaque, the two big culprits behind Alzheimer's and Parkinson's. Learn how they impact cognitive decline. 



Dr. Weaver enlisted Dr. Ross Mancini, a research fellow in medicinal chemistry and Yanfei Wang, a biologist, to help. The team chose to investigate three different types of coffee – light roast, dark roast, and decaffeinated dark roast.

3 Roast Coffees - Unexpected Results

"The caffeinated and de-caffeinated dark roast both had identical potencies in our initial experimental tests," says Dr. Mancini. "So we observed early on that its protective effect could not be due to caffeine."

Dr. Mancini then identified a group of compounds known as phenylindanes, which emerge as a result of the roasting process for coffee beans. Phenylindanes are unique in that they are the only compound investigated in the study that prevent – or rather, inhibit – both beta amyloid and tau, two protein fragments common in Alzheimer's and Parkinson's, from clumping. "So phenylindanes are a dual-inhibitor. Very interesting, we were not expecting that." says Dr. Weaver.

Dark Roast More Protective

As roasting leads to higher quantities of phenylindanes, dark roasted coffee appears to be more protective than light roasted coffee.

"It's the first time anybody's investigated how phenylindanes interact with the proteins that are responsible for Alzheimer's and Parkinson's," says Dr. Mancini. "The next step would be to investigate how beneficial these compounds are, and whether they have the ability to enter the bloodstream, or cross the blood-brain barrier."

Natural Compound

The fact that it's a natural compound versus synthetic is also a major advantage, says Dr. Weaver.

"Mother Nature is a much better chemist than we are and Mother Nature is able to make these compounds. If you have a complicated compound, it's nicer to grow it in a crop, harvest the crop, grind the crop out and extract it than try to make it."

But, he admits, there is much more research needed before it can translate into potential therapeutic options.

"What this study does is take the epidemiological evidence and try to refine it and to demonstrate that there are indeed components within coffee that are beneficial to warding off cognitive decline. It's interesting but are we suggesting that coffee is a cure? Absolutely not."

Sunday, April 22, 2018

Extra glass of wine a day 'will shorten your life by 30 minutes'

But if it reduces my chances of Alzheimers I'll take that tradeoff.  Ask your doctor if coffee or wine is more likely to prevent dementia. I'm doing both, don't want to take any chances.

Wine Cleans Alzheimer's Plaque 

Wine experts less vulnerable to Alzheimer's, study says

Coffee May Lower Your Risk of Dementia Feb. 2013

 

Extra glass of wine a day 'will shorten your life by 30 minutes'  


Drinking will shorten your life, according to a study that suggests every glass of wine or pint of beer over the daily recommended limit will cut half an hour from the expected lifespan of a 40-year-old.

Those who think a glass of red wine every evening will help keep the heart healthy will be dismayed. The paper, published in the Lancet medical journal, says five standard 175ml glasses of wine or five pints a week is the upper safe limit – about 100g of alcohol, or 12.5 units in total. More than that raises the risk of stroke, fatal aneurysm (a ruptured artery in the chest), heart failure and death.

The risks for a 40-year-old of drinking over the recommended daily limit were comparable to smoking, said one leading scientist. “Above two units a day, the death rates steadily climb,” said David Spiegelhalter, Winton professor for the public understanding of risk at the University of Cambridge.

“The paper estimates a 40-year-old drinking four units a day above the guidelines [the equivalent of drinking three glasses of wine in a night] has roughly two years’ lower life expectancy, which is around a 20th of their remaining life. This works out at about an hour per day. So it’s as if each unit above guidelines is taking, on average, about 15 minutes of life, about the same as a cigarette.


“Of course, it’s up to individuals whether they think this is worthwhile.”

There is still a small benefit to drinking, which has been much flagged in the past. It does reduce the chance of a non-fatal heart attack. But, said Dr Angela Wood, from the University of Cambridge, lead author of the study, “this must be balanced against the higher risk associated with other serious – and potentially fatal – cardiovascular diseases.”

The big international study supports the new UK recommended limits of a maximum of 14 units a week for both men and women, which were fiercely contested when introduced by England’s chief medical officer, Dame Sally Davies, in 2016. Other countries with higher limits should reduce them, it suggests. They include Italy, Portugal and Spain as well as the US, where for men the recommended limit is almost double.

Advertisement
The study included data from nearly 600,000 current drinkers included in 83 studies carried out in 19 countries. About half the participants reported drinking more than 100g per week, and 8.4% drank more than 350g per week. Early deaths rose when more than 100g per week, which is five to six glasses of wine or pints of beer, was consumed.

A 40-year-old who drank up to twice that amount (100 to 200g) cut their life expectancy by six months. Between 200g and 350g a week, they lost one to two years of life, and those who drank more than 350g a week shortened their lives by four to five years.

Tim Chico, professor of cardiovascular medicine at the University of Sheffield, said smokers lost on average 10 years of life. “However, we think from previous evidence that it is likely that people drinking a lot more than 43 units are likely to lose even more life expectancy, and I would not be surprised if the heaviest drinkers lost as many years of life as a smoker.




“This study makes clear that on balance there are no health benefits from drinking alcohol, which is usually the case when things sound too good to be true.”(Really? Don't you read research at all?)

Spiegelhalter said it was “a massive and very impressive study. It estimates that, compared to those who only drink a little, people who drink at the current UK guidelines suffer no overall harm in terms of death rates, and have 20% fewer heart attacks.”

Prof Jeremy Pearson, associate medical director at the British Heart Foundation, which part-funded the study, called it “a serious wakeup call for many countries.”

Dr Tony Rao, visiting lecturer in old age psychiatry at King’s College London, said the study “highlights the need to reduce alcohol related harm in baby boomers, an age group currently at highest risk of rising alcohol misuse”. It did not take into account the possibility of mental disorders such as dementia, which could accompany the other health problems drinkers incur.

In a commentary in the Lancet, Profs Jason Connor and Wayne Hall from the University of Queensland Centre for Youth Substance Abuse Research in Australia, anticipated that the suggestion of lowering recommended drinking limits will come up against opposition.

“The drinking levels recommended in this study will no doubt be described as implausible and impracticable by the alcohol industry and other opponents of public health warnings on alcohol. Nonetheless, the findings ought to be widely disseminated and they should provoke informed public and professional debate.”

 


Wednesday, February 21, 2018

Wine Cleans Alzheimer's Plaque

Bet your doctor won't tell you about this.
http://www.alzheimersweekly.com/2018/02/wine-cleans-alzheimers-plaque.html
DIET VIDEO & ARTICLE:

A new study shows how a daily glass of wine helps clean the brain of Alzheimer's plaque.




While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appears in the journal Scientific Reports, shows that low levels of alcohol consumption tamp down inflammation and helps the brain clear away toxins, including those associated with Alzheimer’s disease.

“Prolonged intake of excessive amounts of ethanol is known to have adverse effects on the central nervous system,” said Maiken Nedergaard, M.D., D.M.Sc., co-director of the Center for Translational Neuromedicine at the University of Rochester Medical Center (URMC) and lead author of the study.  “However, in this study we have shown for the first time that low doses of alcohol are potentially beneficial to brain health, namely it improves the brain’s ability to remove waste.”

The finding adds to a growing body of research that point to the health benefits of low doses of alcohol. While excessive consumption of alcohol is a well-documented health hazard, many studies have linked lower levels of drinking with a reduced risk of cardiovascular diseases as well as a number of cancers.

Nedergaard’s research focuses on the glymphatic system, the brain’s unique cleaning process that was first described by Nedergaard and her colleagues in 2012.  They showed how cerebral spinal fluid (CSF) is pumped into brain tissue and flushes away waste, including the proteins beta amyloid and tau that are associated with Alzheimer’s disease and other forms of dementia.  Subsequent research has shown that the glymphatic system is more active while we sleep, can be damaged by stroke and trauma, and improves with exercise.

The new study, which was conducted in mice, looked at the impact of both acute and chronic alcohol exposure.  When they studied the brains of animals exposed to high levels of alcohol over a long period of time, the researchers observed high levels of a molecular marker for inflammation, particularly in cells called astrocytes which are key regulators of the glymphatic system.  They also noted impairment of the animal’s cognitive abilities and motor skills.

Animals that were exposed to low levels of alcohol consumption, analogous to approximately 2 ½ drinks per day, actually showed less inflammation in the brain and their glymphatic system was more efficient in moving CSF through the brain and removing waste, compared to control mice who were not exposed to alcohol.  The low dose animals’ performance in the cognitive and motor tests was identical to the controls.

“The data on the effects of alcohol on the glymphatic system seemingly matches the J-shaped model relating to the dose effects of alcohol on general health and mortality, whereby low doses of alcohol are beneficial, while excessive consumption is detrimental to overall health” said Nedergaard.  “Studies have shown that low-to-moderate alcohol intake is associated with a lesser risk of dementia, while heavy drinking for many years confers an increased risk of cognitive decline.  This study may help explain why this occurs.  Specifically, low doses of alcohol appear to improve overall brain health.”

Additional co-authors include Iben Lundgaard, Wei Wang, Allison Eberhardt, Hanna Vinitsky, Benjamin Reeves, Sisi Peng, Nanhong Lou, and Rashid Hussein with URMC.  Nedergaard maintains research labs at both URMC and the University of Copenhagen in Denmark.  The study was funding with support from the Department of Navy’s Office of Naval Research, the National Institute of Neurological Disorders and Stroke, and the National Institute on Aging.

Alzheimer’s Dramatically Reversed For The First Time

You will want your doctor to keep track of actual interventions that come from this.  If your doctor and hospital can't get human testing going: THEY ARE MASSIVELY INCOMPETENT! No excuses are allowed for not doing this!

Alzheimer’s Dramatically Reversed For The First Time


The first time scientists have been able to completely clear the brain of Alzheimer’s-related protein tangles.
Alzheimer’s has been reversed in mice for the first time, raising the hopes of a drug to combat the disease.
Decreasing the levels of a key enzyme — called BACE1 — reduced the levels of amyloid plaques, which are linked to Alzheimer’s.
The mice’s brains were eventually completely free of these tangles and their cognition improved.
This is the first time scientists have been able to clear the brain of these protein tangles.
It is possible a drug could be developed to help target this enzyme.
Professor Riquiang Yan, who led the study, said:
“To our knowledge, this is the first observation of such a dramatic reversal of amyloid deposition in any study of Alzheimer’s disease mouse models.”
For the study, the scientists created mice that produce lower levels of the BACE1 protein over time.
The mice were also engineered to develop Alzheimer’s.
After developing Alzheimer’s at 75 days old, these mice were then clear of the plaques in their brain at 10 months old.
Effectively, one genetic abnormality cured the other.
Their cognition was also improved, although not fully.
Professor Yan said:
“Our study provides genetic evidence that preformed amyloid deposition can be completely reversed after sequential and increased deletion of BACE1 in the adult.
Our data show that BACE1 inhibitors have the potential to treat Alzheimer’s disease patients without unwanted toxicity.
Future studies should develop strategies to minimize the synaptic impairments arising from significant inhibition of BACE1 to achieve maximal and optimal benefits for Alzheimer’s patients.”

The study was published in the Journal of Experimental Medicine (Hu et al., 2018).